Latest Biotechnology Earnings News

Page 1 of 1

CSL’s $1.9b NPATA Dip Masks Ambitious Growth and $750m Buy-Back Boost

CSL Limited reported a 7% decline in underlying NPATA to US$1.9 billion for the half-year, weighed down by restructuring costs and impairments, yet maintains full-year guidance and expands its share buy-back program.

Ada Torres

11 Feb 2026

Top